GE Healthcare said it launched its next-generation monitoring solution, CARESCAPE CANVAS, in Korea following recent approval from the Ministry of Food and Drug Safety.

This solution, which received EU authorization in 2022 and U.S. FDA approval in 2023, is already being utilized in hospitals worldwide as a standardized, integrated monitoring system.

CARESCAPE CANVAS is designed to provide personalized care and monitoring for individual patients with a single monitor.

Its standardized model allows for comprehensive, integrated monitoring across the hospital ecosystem.

This system leverages the company’s FlexAcuity technology, which is based on 50 years of clinical parameters and algorithms. It offers flexibility tailored to each patient's unique treatment needs and severity levels.

The modular design of CARESCAPE CANVAS also ensures compatibility across the entire hospital ecosystem, allowing hospitals to add functions and equipment without the need for additional platforms, thus maximizing their investment value.

The solution also aligns with GE Healthcare’s Net Zero mission as it is produced using 100 percent renewable energy. The new model also reduces power consumption by 25 percent compared to previous versions and significantly reduces packaging volume and mass, underscoring GE Healthcare’s commitment to sustainability.

“GE Healthcare is committed to developing technologies that improve outcomes for both healthcare professionals and patients through comprehensive medical solutions,” GE HealthCare Korea CEO Kim Yong-duk said. “CARESCAPE CANVAS aligns with this vision, offering standardized integration across hospital ecosystems while providing personalized monitoring for patients.”

This will significantly enhance the quality of medical services, particularly in critical care environments where monitoring is crucial, Kim added.